Loading…
Aptevo Therapeutics Inc. is projected to decline to $3.88 by 2027, a -2% move from its current price of $3.95. APVO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.81 | $3.95 | $4.09 | 0.00% |
| Aug 6 | $3.76 | $3.95 | $4.15 | 0.00% |
| Aug 7 | $3.72 | $3.95 | $4.20 | 0.00% |
| Aug 8 | $3.68 | $3.95 | $4.24 | 0.00% |
| Aug 9 | $3.65 | $3.95 | $4.27 | 0.00% |
| Aug 10 | $3.63 | $3.95 | $4.30 | 0.00% |
| Aug 11 | $3.60 | $3.95 | $4.33 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.60 | $3.95 | $4.33 | 0.00% |
| Week 2 | $3.47 | $3.95 | $4.50 | -0.01% |
| Week 3 | $3.37 | $3.95 | $4.63 | -0.01% |
| Week 4 | $3.28 | $3.95 | $4.75 | -0.01% |
| Week 5 | $3.21 | $3.95 | $4.86 | -0.02% |
| Week 6 | $3.15 | $3.95 | $4.95 | -0.02% |
| Week 7 | $3.09 | $3.95 | $5.04 | -0.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aptevo Therapeutics Inc. is a clinical-stage research and development biotechnology company focused on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myeloid leukemia.
It also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc.
was incorporated in 2016 and is headquartered in Seattle, Washington.
APVO is currently priced at $4.21 with a market capitalization of $5.25M and a rank of 5086.
The current price level sits within a forecast landscape that shows a sequence of years with varying upside potential. The 2026 average price is $4.21 (min $3.94, max $5.51) with ROI 0 and a NEUTRAL sentiment. These figures illustrate a base-case path around the current price.
Looking further out, the 2030 average price is $5.52 (min $3.84, max $8.61) with ROI 31.1 and a BULLISH sentiment. The 2050 average price is $12.05 (min $5.52, max $25.30) with ROI 186.1 and a BULLISH sentiment. In between, the forecast covers years such as 2029 ($5.33 avg, ROI 26.6; BULLISH), 2032 ($5.06 avg, ROI 20.2; BULLISH), and 2035 ($6.80 avg, ROI 61.6; BULLISH).
A major floor 12.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.3% away) — a key level to hold.
The nearest ceiling, 20.4% above — a clean break opens room to run.
A major ceiling 42.0% above — clearing it would confirm fresh momentum.
Key APVO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APVO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.13 | Sell | $4.16 | Sell |
| MA 10 | $4.30 | Sell | $4.24 | Sell |
| MA 20 | $4.35 | Sell | $4.35 | Sell |
| MA 50 | $4.60 | Sell | $4.61 | Sell |
| MA 100 | $4.66 | Sell | $9.65 | Sell |
| MA 200 | $10.40 | Sell | $1,125.53 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.86 | Neutral |
| Stoch RSI (14) | 24.59 | Neutral |
| CCI (20) | -75.06 | Neutral |
| Williams %R (14) | -83.23 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -10.07 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 16.77 | Buy |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -0.33 | Sell |
| Ultimate (7,14,28) | 34.01 | Neutral |
| Momentum (10) | -0.63 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 4.01 | Sell |
| ADX (14) | 14.16 | Neutral |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 40, indicating limited upside momentum in the near term. The SMA50 is $4.65 and the SMA200 is $11.05, biasing longer-term trend signals higher if price strength improves.
The near-term price range spans $3.29 to $5.38 over the last 30 days, with support at $3.94 and resistance at $4.86. These levels provide a framework for traders watching short-term price action while the broader fundamentals remain tied to the long-run forecast path.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.94 | $3.95 | $5.12 | 0% | Neutral | |
| $3.02 | $3.88 | $5.32 | -2% | Neutral | |
| $2.75 | $3.67 | $5.27 | -7% | Neutral | |
| $3.57 | $4.92 | $7.32 | +24% | Bullish | |
| $3.65 | $5.16 | $7.92 | +31% | Bullish | |
| $3.15 | $4.57 | $7.20 | +16% | Neutral | |
| $3.19 | $4.74 | $7.63 | +20% | Neutral | |
| $2.90 | $4.41 | $7.26 | +12% | Neutral | |
| $3.15 | $4.89 | $8.20 | +24% | Bullish | |
| $3.97 | $6.29 | $10.73 | +59% | Bullish | |
| $3.75 | $6.52 | $11.97 | +65% | Bullish | |
| $5.50 | $11.32 | $23.09 | +187% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.94 | $3.95 | $4.87 | +0.00% |
| September 2026 | $3.44 | $4.10 | $5.04 | +3.77% |
| October 2026 | $3.28 | $3.95 | $4.93 | -3.68% |
| November 2026 | $3.22 | $3.90 | $4.92 | -1.28% |
| December 2026 | $3.29 | $4.02 | $5.12 | +3.05% |
Click any year to see its month-by-month APVO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Aptevo Therapeutics Inc.'s 2026 outlook centres on $3.95, within a $3.94 to $5.12 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, APVO could reach as high as $5.32, with a base case around $3.88 and support toward $3.02 — roughly -2% from $3.95. Price action looks broadly range-bound.
Expect APVO to range from $2.75 to $5.27 through 2028. The $3.67 average target implies a -7% move from current prices. That is -5% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The APVO price prediction for 2029 points to an average of $4.92 (low $3.57, high $7.32) — a potential gain of +24% on today's $3.95. Momentum favours further upside here.
In 2030, APVO is projected to trade between $3.65 and $7.92, averaging $5.16 — a potential gain of +31% from today's $3.95. That is up +5% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Aptevo Therapeutics Inc.'s 2031 outlook centres on $4.57, within a $3.15 to $7.20 range. That is -11% versus the projected 2030 average. That marks a +16% change versus current levels. Price action looks broadly range-bound.
By 2032, APVO could reach as high as $7.63, with a base case around $4.74 and support toward $3.19 — roughly +20% from $3.95. A consolidation phase looks the most probable path here.
Expect APVO to range from $2.90 to $7.26 through 2033. The $4.41 average target implies a +12% move from current prices. That is -7% versus the projected 2032 average. Price action looks broadly range-bound.
The APVO price prediction for 2034 points to an average of $4.89 (low $3.15, high $8.20) — a potential gain of +24% on today's $3.95. Buyers look set to stay in control over this stretch.
In 2035, APVO is projected to trade between $3.97 and $10.73, averaging $6.29 — a potential gain of +59% from today's $3.95. That is up +29% on the projected 2034 average. Momentum favours further upside here.
Aptevo Therapeutics Inc.'s 2040 outlook centres on $6.52, within a $3.75 to $11.97 range. That is up +4% on the projected 2035 average. That marks a +65% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, APVO could reach as high as $23.09, with a base case around $11.32 and support toward $5.50 — roughly +187% from $3.95. Momentum favours further upside here.
Investing $1,000 in APVO today (≈ 253.164557 APVO) could be worth
$2,866.25
+$1,866.25 (+187%) by 2050 · US Dollar
Based on the average projected APVO price of $11.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APVOwould be worth at today's price.
$1,000 invested in APVO on Jul 31, 2025 (≈ 19.912385 APVO) would be worth
$78.65
-$921.35 (-92.1%) today · 0.08× · US Dollar
Based on a APVO entry price of $50.22 vs. today's $3.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.39 | $899.77 | -10.0% |
| 1 month ago | $4.45 | $887.64 | -11.2% |
| 3 months ago | $4.92 | $802.85 | -19.7% |
| 6 months ago | $7.54 | $523.87 | -47.6% |
| 1 year ago | $50.22 | $78.65 | -92.1% |
| All time (5.0y) ago | $10,924,531 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APVO forecast.
Our base-case forecast reaches $7.90 around 2050.
Implied market cap at $7.90: $9.84M
The multi-year forecast shows periods of constructive upside with rising averages in several later years. Notably, 2029 (avg $5.33, ROI 26.6) and 2030 (avg $5.52, ROI 31.1) point to continued potential upside, with 2032 (avg $5.06, ROI 20.2), 2034 (avg $5.24, ROI 24.6), and 2035 (avg $6.80, ROI 61.6) reinforcing a bullish trajectory. The 2040 forecast (avg $7.01, ROI 66.6) and the 2050 forecast (avg $12.05, ROI 186.1) mark substantial upside potential if the path is realized.
However, earlier years show more modest outcomes, including 2027 (avg $4.06, ROI -3.5) and 2028 (avg $3.92, ROI -6.8), underscoring the presence of downside risk within a volatile growth scenario. These figures illustrate that estimates are not guarantees and that outcomes may vary with clinical development milestones and market factors.
Tap a question to reveal the answer.
2030 avg $5.52, min $3.84, max $8.61, ROI 31.1, sentiment BULLISH.
The forecast shows a mix of outcomes, including years with positive ROI (e.g., 2029 26.6, 2030 31.1, 2035 61.6, 2040 66.6, 2050 186.1) and years with negative ROI (e.g., 2027 -3.5, 2028 -6.8). These are estimates and not guarantees.
Yes. The max prices in the forecast include $11.87 (2035), $13.20 (2040), and $25.30 (2050), indicating a path to $10 is plausible within those horizons.
avg $12.05, min $5.52, max $25.30, ROI 186.1, sentiment BULLISH.
Aptevo Therapeutics Inc. Community Discussion
0Share your Aptevo Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.